Charles Schwab Investment Management Inc. Increases Stake in ASP Isotopes Inc. (NASDAQ:ASPI)

Charles Schwab Investment Management Inc. raised its position in ASP Isotopes Inc. (NASDAQ:ASPI) by 31.6% in the 4th quarter, Holdings Channel reports. The fund owned 158,226 shares of the company’s stock after acquiring an additional 37,948 shares during the period. Charles Schwab Investment Management Inc.’s holdings in ASP Isotopes were worth $717,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. SVB Wealth LLC purchased a new stake in ASP Isotopes in the 4th quarter valued at approximately $49,000. Boston Financial Mangement LLC acquired a new stake in shares of ASP Isotopes in the 4th quarter valued at approximately $50,000. Rhumbline Advisers boosted its stake in shares of ASP Isotopes by 69.1% in the fourth quarter. Rhumbline Advisers now owns 60,363 shares of the company’s stock valued at $273,000 after buying an additional 24,664 shares in the last quarter. Almanack Investment Partners LLC. purchased a new stake in shares of ASP Isotopes in the fourth quarter valued at approximately $68,000. Finally, Hanson & Doremus Investment Management acquired a new position in ASP Isotopes during the fourth quarter worth $27,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

ASP Isotopes Price Performance

ASP Isotopes stock opened at $4.69 on Tuesday. The company has a market cap of $334.82 million, a P/E ratio of -7.69 and a beta of 3.66. ASP Isotopes Inc. has a one year low of $1.86 and a one year high of $9.33. The business has a fifty day moving average of $4.99 and a two-hundred day moving average of $4.95. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.